Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Phio Pharmaceuticals Corp.

PHIONASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Sep 29, 2026Accepted Sep 29, 2026, 4:01 PM EDTFiling CIK 1533040Accession 0001683168-26-007483
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-09-28
Issuer
Phio Pharmaceuticals Corp.
Issuer CIK
0001533040
Trading symbol
PHIO

Reporting owner 1

Name
Bitterman Robert J
Reporting owner CIK
0001304395
Relationship
Director · Officer
Officer title
Chairman, Pres. & CEO
Address
C/O PHIO PHARMACEUTICALS CORP., 411 SWEDELAND RD., STE 23-1080, KING OF PRUSSIA, PA, 19406

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock, $.0001 par value2026-09-28A · Form 4400,000[F1]A0764,871[F2]D
Table key
A · Form 4
Acquisition by grant, award or otherwise under Rule 16b-3(d)
A
Acquired
D
Direct

Footnotes

F1
Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.↩ 1
F2
Includes shares of common stock underlying unvested restricted stock units.↩ 1

Signature 1

Signed
/s/ Lisa C. Carson, Attorney-in-fact
Date
2026-09-29

Company context

Phio (“Phio”, “we”, “our”, or the “Company”) is a clinical stage biotechnology company whose proprietary INTASYL® small interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free future.

Current securities

Historical securities (2)

Recent company filings

  1. 4 filingNov 10, 2026
  2. 10-Q filingNov 5, 2026
  3. Results of Operations and Financial ConditionNov 5, 2026
  4. Other EventsOct 13, 2026
  5. S-8 filingSep 28, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.